About this trial

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.

Eligibility criteria

Qualifiers

Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only).

Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis.

Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) [Cohort I] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only)

Age > 18 years

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Interview
  • Medical Chart Review
  • Questionnaire Administration

Treatment groups

1,200 Participants
are divided into 1 treatment group

Locations

10
Arizona
Banner - MD Anderson Cancer Center85234, Gilbert United States
California
Scripps - MD Anderson Cancer Center92037, La Jolla United States
Colorado
Banner - MD Anderson Cancer Center - Northern Colorado80631, Greeley United States
Florida
Baptist - MD Anderson Cancer Center32207, Jacksonville United States

Sponsors and collaborators

M.D. Anderson Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Texas Appropriation for Rare and Aggressive diseases

Collaborator